Список литературы

1. Дедков И.П., Захарычев В.Д. Первичные новообразования средостения. К.: Здоровье, 1982. 176 p.

2. Трахтенберг А.Х. Опухоли средостения//Комбинированное и комплексное лечение больных со злокачественными опухолями/ed. Чиссов В.И. М., 1989. P. 278 - 290.

3. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г.//Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Vol. 21, N 2. P. прил. 2.

4. Eralp Y. et al. Resectable Thymoma: Treatment Outcome and Prognostic Factors in the Late Adolescent and Adult Age Group//Cancer Invest. 2003. Vol. 21, N 5. P. 737 - 743.

5. Wick M.R. et al. Primary mediastinal carcinoid tumors.//Am. J. Surg. Pathol. 1982. Vol. 6, N 3. P. 195 - 205.

6. Морозов А.И., Сазонов А.М., Коршунов А.И. Лучевая и комплексная химиолучевая терапия злокачественных опухолей вилочковой железы после паллиативных хирургических вмешательств//Советская медицина. 1991. Vol. 7. P. 53 - 56.

7. Харченко В.П., Саркисов Д.., Ветшев П.С. Болезни вилочковой железы. М.: Триада-Х, 1998. 179 - 83 p.

8. Пикин О.В. et al. Опухоли средостения: сборник под ред. академика РАН, профессора А.Д. Каприна. М.: Молодая гвардия, 2019. 232 p.

9. Сакаева Д.Д., Лазарева Д.Н. Клиническая фармакология в онкологии. М.: Медицинское информационное агентство, 2007. 336 p.

10. Орлова Р.В. et al. Практические рекомендации по лечению анемии при злокачественных новообразованиях//Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2019. Vol. 9. P. 7.

11. Трякин А.А. Лекарственное и комбинированное лечение несеминомных герминогенных опухолей у мужчин. М.: Автореф. дис. ... д-ра мед. наук, 2015. 254 p.

12. Трякин А.А., Гладков О.А., Матвеев В.Б. Практические рекомендации по лекарственному лечению герминогенных опухолей яичка//Злокачественные опухоли. 2016. Vol. 4, N спецвып. 2. P. 353 - 366.

13. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.//J. Clin. Oncol. 1997. Vol. 15, N 2. P. 594 - 603.

14. Honecker F. et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.//Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, N 8. P. 1658 - 1686.

15. Пирогов А.И., Полоцкий Б.Е., Лактионов К.П. Характеристика тимом и их прогноз//Советская медицина. 1983. Vol. 12. P. 99 - 102.

16. Silvestri G.A. et al. Endoscopic ultrasound with fine-needle aspiration in the Diagnosis and staging of lung cancer//Ann. Thorac. Surg. 1996. Vol. 61, N 5. P. 1441 - 1446.

17. Herth F.J.F. et al. Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes//Thorax. 2006. Vol. 61, N 9. P. 795 - 798.

18. Барчук А.С., Лемехов В.Г., Клименко В.Н. Диагностические и лечебные возможности видеоторакоскопии в условиях онкологической торакальной клиники//Высокие технологии в онкологии Материалы 5-го Всероссийского съезда онкологов. 2000. Vol. 2. P. 9 - 11.

19. Шевченко Ю.А. et al. Сорокалетний опыт хирургического лечения генерализованной миастении//Хирургия. 2004. Vol. 5. P. 32 - 38.

20. Ветшев П.С. et al. Хирургическое лечение тимом у больных генерализованной миастенией//Хирургия. 2003. Vol. 10. P. 15 - 19.

21. Ганул В.Л., Ганул А.В. О диагностике и лечении опухолей вилочковой железы//Советская медицина. 1988. Vol. 6. P. 13 - 17.

22. Греджев А.Ф., Ступаченко О.Н., Кравец В.С. Хирургическое лечение новообразований вилочковой железы//Грудная хирургия. 1986. Vol. 4. P. 59 - 63.

23. Kondo K. Optimal therapy for thymoma//J. Med. Investig. 2008. Vol. 55, N 1, 2. P. 17 - 28.

24. Boston B. Chemotherapy of invasive thymoma.//Cancer. 1976. Vol. 38, N 1. P. 49 - 52.

25. Loehrer P.J. et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.//J. Clin. Oncol. American Society of Clinical Oncology, 1994. Vol. 12, N 6. P. 1164 - 1168.

26. Loehrer P.J. et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.//J. Clin. Oncol. American Society of Clinical Oncology, 1997. Vol. 15, N 9. P. 3093 - 3099.

27. Giaccone G. et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.//J. Clin. Oncol. Lippincott Williams and Wilkins, 1996. Vol. 14, N 3. P. 814 - 820.

28. Lemma G.L. et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma//J. Clin. Oncol. 2011. Vol. 29, N 15. P. 2060 - 2065.

29. Loehrer P.J. et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial//Cancer. 2001. Vol. 91, N 11. P. 2010 - 2015.

30. Мачаладзе З.О. Опухоли средостения (дифференциальная диагностика и лечение). М.: Автореф. дис. ... д-ра мед. наук, 2008. 506 p.

31. Ахмедов Б.Б. Внутригрудные первичные и метастатические герминогенные опухоли (клиника, диагностика, лечение). М.: Автореф. дис. ... канд. мед. наук, 2004. 144 p.

32. Loehrer P.J. et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.//J. Clin. Oncol. 1998. Vol. 16, N 7. P. 2500 - 2504.

33. Тюляндин С.А., Переводчикова Н.И., Носов Д.А. Минимальные клинические рекомендации Европейского общества медицинской онкологии. М.: Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2010. 146 p.

34. Переводчикова Н.И. Руководство по химиотерапии опухолевых заболеваний. М.: Практическая медицина, 2005. 699 p.

35. Tryakin A., Fedyanin M., Mitin A. Complete disappearance of retroperitoneal lymph nodes after induction chemotherapy in advanced nonseminomatous germ cell tumors (NSGCT): Is there a place for adjunctive surgery?//J Clin Oncol. 2012. Vol. 30, N 15, suppl. P. 15029.

36. Давыдов М.М., Полоцкий Б.Е., Мачаладзе З.О. Мезенхимальные опухоли средостения: пособие для врачей. М.: Издательская группа РОНЦ им. Н.Н. Блохина РАМН, 2015.

37. Ткачев С.И. et al. Консервативное лечение больных агрессивным фиброматозом//Вестник РОНЦ РАМН им. Блохина РАМН. 2004. Vol. 3. P. 61 - 66.

38. Бирюков Ю.В., Чарнецкий Р.И., Годжелло Э.А. Сосудистые новообразования средостения//Хирургия. 1991. Vol. 4. P. 3 - 7.

39. Shenoy S.S. et al. Mediastinal lymphangioma.//J. Surg. Oncol. 1978. Vol. 10, N 6. P. 523 - 528.

40. Cakir E. et al. Primary mediastinal haemangiopericytoma--an unusual cause of massive haemoptysis in a young woman.//Acta Chir. Belg. 2010. Vol. 110, N 2. P. 235 - 237.

41. Мачаладзе З.О. et al. Опухоли мягких тканей средостения//Грудная и сердечно-сосудистая хирургия. 2008. Vol. 1. P. 59 - 65.

42. Antic T., Staerkel G. Mediastinal epithelioid hemangioendothelioma metastatic to lymph nodes and pleural fluid: report of a case.//Diagn. Cytopathol. 2010. Vol. 38, N 2. P. 113 - 116.

43. Вишневский А.А., Адамян А.А. Хирургия средостения. М.: Медицина, 1977. 138 - 194 p.

44. Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes.//Am. J. Phys. Med. Rehabil. 2013. Vol. 92, N 8. P. 715 - 727.

45. Nilsson H. et al. Is preoperative physical activity related to post-surgery recovery? A cohort study of patients with breast cancer.//BMJ Open. 2016. Vol. 6, N 1. P. e007997.

46. Eustache J. et al. Enhanced recovery after pulmonary surgery//J. Thorac. Dis. 2018. Vol. 10, N S32. P. S3755 - S3755.

47. Medbery R.L., Fernandez F.G., Khullar O.V. ERAS and patient reported outcomes in thoracic surgery: a review of current data.//J. Thorac. Dis. AME Publications, 2019. Vol. 11, N Suppl 7. P. S976 - S986.

48. Field T. Massage therapy research review//Complement. Ther. Clin. Pract. 2016. Vol. 24. P. 19 - 31.

49. Oren R. et al. Musculoskeletal Cancer Surgery/ed. Malawer. Springer, 2013. 583 - 593 p.

50. Segal R. et al. Exercise for people with cancer: a systematic review.//Curr. Oncol. 2017. Vol. 24, N 4. P. e290 - e315.

51. Boyd C. et al. The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations.//Pain Med. 2016. Vol. 17, N 8. P. 1553 - 1568.

52. Stout N.L. et al. A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005 - 2017).//PM R. 2017. Vol. 9, N 9S2. P. S347 - S384.

53. Hu M., Lin W. Effects of exercise training on red blood cell production: implications for anemia.//Acta Haematol. 2012. Vol. 127, N 3. P. 156 - 164.

54. Bland K.A. et al. Impact of exercise on chemotherapy completion rate: A systematic review of the evidence and recommendations for future exercise oncology research.//Crit. Rev. Oncol. Hematol. 2019. Vol. 136. P. 79 - 85.

55. Mustian K.M. et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.//JAMA Oncol. 2017. Vol. 3, N 7. P. 961 - 968.

56. Kinkead B. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial.//Cancer. 2018. Vol. 124, N 3. P. 546 - 554.

57. Streckmann F. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review.//Sports Med. 2014. Vol. 44, N 9. P. 1289 - 1304.

58. Rick O. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study.//Bioelectromagnetics. 2017. Vol. 38, N 2. P. 85 - 94.

59. M. et al. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain.//J. Rehabil. Med. 2014. Vol. 46, N 5. P. 454 - 460.

60. Oberoi S. et al. Effect of Prophylactic Low Level Laser Therapy on Oral Mucositis: A Systematic Review and Meta-Analysis//PLoS One/ed. Hamblin M. 2014. Vol. 9, N 9. P. e107418.

61. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy//J. Thorac. Dis. 2018. Vol. 10, N S35. P. S4391 - S4399.

62. Kessels E., Husson O., Van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis//Neuropsychiatr. Dis. Treat. 2018. Vol. Volume 14. P. 479 - 494.

63. Rief H. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial.//BMC Cancer. 2014. Vol. 14, N 1. P. 67.

64. Bensadoun R.-J., Nair R.G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy//Photomed. Laser Surg. 2015. Vol. 33, N 10. P. 487 - 491.

65. Temoshok L. Biopsychosocial studies on cutaneous malignant melanoma: psychosocial factors associated with prognostic indicators, progression, psychophysiology and tumor-host response.//Soc. Sci. Med. 1985. Vol. 20, N 8. P. 833 - 840.

66. Devine D. et al. The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment.//Psychooncology. 2003. Vol. 12, N 5. P. 453 - 462.

67. Folkman S. et al. Appraisal, coping, health status, and psychological symptoms.//J. Pers. Soc. Psychol. 1986. Vol. 50, N 3. P. 571 - 579.

68. Fawzy F.I. et al. A structured psychiatric intervention for cancer patients. I. Changes over time in methods of coping and affective disturbance.//Arch. Gen. Psychiatry. 1990. Vol. 47, N 8. P. 720 - 725.

69. Honnings J., Gaissert H.A. Tumors of the Trachea//ESTS Textbook of Thoracic Surgery/ed. Kuzdzal J. Cracow: Medycyna Praktyczna, 2014. P. 359 - 373.

70. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET C.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. - PubMed - NCBI//Am J Clin Oncol. 1982. Vol. 5, N 6. P. 649 - 655.

71. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer//Evaluation of chemotherapeutic agents/ed. MacLeod C. New York: Columbia University Press, 1949. P. 191 - 205.

72. Eisenhauer E.A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)//Eur. J. Cancer. 2009. Vol. 45, N 2. P. 228 - 247.

73. Hawker G.A. et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).//Arthritis Care Res. (Hoboken). 2011. Vol. 63 Suppl 11, N S11. P. S240 - 52.

74. Ohnhaus E.E., Adler R. Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale.//Pain. 1975. Vol. 1, N 4. P. 379 - 384.

75. Nicholson AG, Detterbeck FC, Marino M et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9: s73 - s80.

76. Kondo K, Van Schil P, Detterbeck FC et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9: s81 - s87.

77. Detterbeck FC, Stratton K, Giroux D et al. The IASLC/ITMIG thymic epithelial tumors staging project: proposals for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9: s65 - s72.

78. Дидаев С.И. Антитела к аутоантигенным мишеням при миастении и их значение в клинической практике. Нервно-мышечные болезни. 2014; 2: 6 - 15

79. Санадзе А.Г. Миастения и миастенические синдромы: руководство. М.: Литтера, 2012. 256 с.

80. Lindstrom J. Antibody specificities in autoimmune myasthenia gravis. Neuromuscular Diseases. N. Y., 1984. P. 481 - 495.

81. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009; 115: 5413 - 5420

82. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 2009; 87: 1641 - 1647.

83. Basse C, Thureau S, Bota S, et al. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol 2017; 12: 1715 - 1722.

84. Tateishi Y, Horita N, Namkoong H, et al. Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients. J Thorac Oncol 2021; 16: 677 - 685.

85. Hamaji M, Shah RM, Ali SO, et al. A Meta-Analysis of Postoperative Radiotherapy for Thymic Carcinoma. Ann Thorac Surg 2017; 103: 1668 - 1675.

86. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010; 76: 440 - 445.

87. Ruffini E, et al. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. Eur J Cardiothorac Surg 2019; 55: 601 - 609.

88. Litvak AM, Woo K, Hayes S, et al. Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol 2014; 9: 1810 - 1815.

89. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002; 94: 3115 - 3119.

90. Ahmad U, Yao X, Detterbeck F, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg 2015; 149: 95 - 100, 101. e101 - 102.

91. Mao Y, Wu S. Treatment and survival analyses of completely resected thymic carcinoma patients. Onco Targets Ther 2015; 8: 2503 - 2507.

92. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44: 369 - 379.

93. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991; 68: 30 - 33.

94. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010; 21: 1168 - 1172.

95. Palmieri G, Buonerba C, Ottaviano M, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol 2014; 10: 2141 - 2147.

96. Gbolahan OB, Porter RF, Salter JT, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol 2018; 13: 1940 - 1948.

97. Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol. 2016; 21(3): 531 - 8.

98. Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293 - 299.

99. Zucali PA, De Pas TM, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2018; 36: 342 - 349.

100. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018; 19: 347 - 355.

101. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol 2019; 37: 2162 - 2170.

102. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015; 16: 177 - 186.

103. Клинический алгоритм диагностики и лечения опухолей средостения/А.Б. Рябов, О.В. Пикин, О.А. Александров [и др.]//Хирургия. Журнал им. Н.И. Пирогова. - 2022. - N 5. - С. 43 - 51. - DOI 10.17116/hirurgia202205143. - EDN IJMOEC]

104. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81: 841 - 5.

105. Rea F, Sartori F, Loy M, et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993; 106: 543 - 9.

106. Agatsuma T, Koizumi T, Kanda S, et al. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 2011; 6: 2130 - 4.

107. Yoh K, Goto K, Ishii G, et al. Weekly Chemotherapy with Cisplatin, Vincristine, Doxorubicin, and Etoposide Is an Effective Treatment for Advanced Thymic Carcinoma. Cancer 2003; 98: 926 - 31.

108. Bluthgen MV, Boutros C, Fayard F, et al. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer 2016; 99: 111 - 6.

109. Yoh K, Goto K, Ishii G, et al. Weekly Chemotherapy with Cisplatin, Vincristine, Doxorubicin, and Etoposide Is an Effective Treatment for Advanced Thymic Carcinoma. Cancer 2003; 98: 926 - 31.

110. Grassin F, Paleiron N, M, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 2010; 5: 893 - 7.

111. Antonarelli G, Corti C, Zucali P.A., Perrino M, Manglaviti S, Lo Russo G, Varano G.M et all. Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group. Eur J Cancer. 2022; 174: 31 - 36

112. Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima. Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. Int J Clin Oncol. 2016; 21(3): 531 - 8